(Total Views: 635)
Posted On: 09/22/2021 5:00:13 PM
Post# of 155767
I expect this was the article you got that 20 billion number from?
https://www.ihealthcareanalyst.com/global-non...nt-market/
Further reading shows the author is clueless as to the meds trialed for this condition. This author states the basis for that 20 billion number is predicated on 'expected approvals' of 4 therapeutics...Elafibranor, Obeticholic acid, Simtuzumab and Selonsertib. Below are links showcasing the efficacy of those 4.
https://www.fiercebiotech.com/biotech/genfit-...ase-3-flop
https://www.fda.gov/safety/medical-product-sa...ious-liver
https://www.healio.com/news/hepatology/201808...d-fibrosis
https://www.fiercebiotech.com/biotech/gilead-...ertib-nash
Notice our friends at Gilead have 2 strikes. Leronlimab should take them out of the game completely, and we'll get the whole enchilada!
https://www.ihealthcareanalyst.com/global-non...nt-market/
Further reading shows the author is clueless as to the meds trialed for this condition. This author states the basis for that 20 billion number is predicated on 'expected approvals' of 4 therapeutics...Elafibranor, Obeticholic acid, Simtuzumab and Selonsertib. Below are links showcasing the efficacy of those 4.
https://www.fiercebiotech.com/biotech/genfit-...ase-3-flop
https://www.fda.gov/safety/medical-product-sa...ious-liver
https://www.healio.com/news/hepatology/201808...d-fibrosis
https://www.fiercebiotech.com/biotech/gilead-...ertib-nash
Notice our friends at Gilead have 2 strikes. Leronlimab should take them out of the game completely, and we'll get the whole enchilada!
(4)
(0)
